NO20053344L - Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser. - Google Patents

Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser.

Info

Publication number
NO20053344L
NO20053344L NO20053344A NO20053344A NO20053344L NO 20053344 L NO20053344 L NO 20053344L NO 20053344 A NO20053344 A NO 20053344A NO 20053344 A NO20053344 A NO 20053344A NO 20053344 L NO20053344 L NO 20053344L
Authority
NO
Norway
Prior art keywords
genetically modified
generating
organism
modified organism
active substances
Prior art date
Application number
NO20053344A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053344D0 (no
Inventor
Almut Nitsche
Ekkehard Leberer
Bert Klebl
Anja Stadler
Rosemarie Sollner
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20053344D0 publication Critical patent/NO20053344D0/no
Publication of NO20053344L publication Critical patent/NO20053344L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033Rearing or breeding invertebrates; New breeds of invertebrates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1086Preparation or screening of expression libraries, e.g. reporter assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1072Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1079Screening libraries by altering the phenotype or phenotypic trait of the host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20053344A 2002-12-17 2005-07-08 Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser. NO20053344L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10258885A DE10258885A1 (de) 2002-12-17 2002-12-17 Verfahren zur Generierung eines gentechnisch veränderten Organismus
PCT/EP2003/012870 WO2004055206A1 (de) 2002-12-17 2003-11-18 Verfahren zur generierung eines gentechnisch veränderten organismus für das wirk substanzscreening

Publications (2)

Publication Number Publication Date
NO20053344D0 NO20053344D0 (no) 2005-07-08
NO20053344L true NO20053344L (no) 2005-07-08

Family

ID=32519000

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053344A NO20053344L (no) 2002-12-17 2005-07-08 Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser.

Country Status (14)

Country Link
US (1) US20040143854A1 (ru)
EP (1) EP1576186B1 (ru)
JP (1) JP4630067B2 (ru)
KR (2) KR101215854B1 (ru)
CN (1) CN1726290B (ru)
AT (1) ATE508201T1 (ru)
AU (1) AU2003283409A1 (ru)
CA (1) CA2509333A1 (ru)
DE (2) DE10258885A1 (ru)
HK (1) HK1087734A1 (ru)
NO (1) NO20053344L (ru)
RU (1) RU2376364C2 (ru)
WO (1) WO2004055206A1 (ru)
ZA (1) ZA200504212B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP2008507294A (ja) 2004-07-26 2008-03-13 ダウ グローバル テクノロジーズ インコーポレイティド 菌株遺伝子操作による改善されたタンパク質発現のための方法
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
WO2007104034A2 (en) 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
WO2007124115A2 (en) * 2006-04-20 2007-11-01 Trustees Of Boston College Compositions and methods for identifying inhibitors and activators of cyclic amp phosphodiesterases
ATE522518T1 (de) * 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
AU2008245696B2 (en) 2007-04-27 2013-11-07 Pelican Technology Holdings, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
RU2577988C2 (ru) * 2010-10-29 2016-03-20 Ф. Хоффманн-Ля Рош Аг Муриновая модель воспаления с делецией il33 n-концевого домена
HUP1100657A2 (en) * 2011-11-29 2013-06-28 Eotvos Lorand Tudomanyegyetem Transgenic caenorhabditis elegans
CN110172454B (zh) * 2019-05-23 2020-11-13 浙江大学 一种s-腺苷甲硫氨酸合成酶突变体及其高通量筛选方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030012A1 (en) * 1994-04-26 1995-11-09 Cadus Pharmaceutical Corporation Functional expression of mammalian adenylyl cyclase in yeast
WO1999024563A1 (en) * 1997-11-07 1999-05-20 Iconix Pharmaceuticals, Inc. Surrogate genetics target characterization method
AU2596800A (en) * 1998-12-31 2000-07-31 Iconix Pharmaceuticals, Inc. Method for generating a pathway reporter system
WO2001046403A1 (en) * 1999-12-22 2001-06-28 Iconix Pharmaceuticals, Inc. Synthetic lethal expression screen
WO2002063029A1 (en) * 2001-02-02 2002-08-15 Iconix Pharmaceuticals, Inc. Alteration of phenotype due to heterologous genes
US20030044866A1 (en) * 2001-08-15 2003-03-06 Charles Boone Yeast arrays, methods of making such arrays, and methods of analyzing such arrays

Also Published As

Publication number Publication date
KR20120038025A (ko) 2012-04-20
DE50313671D1 (de) 2011-06-16
EP1576186B1 (de) 2011-05-04
EP1576186A1 (de) 2005-09-21
RU2005122470A (ru) 2006-05-10
RU2376364C2 (ru) 2009-12-20
KR20050085806A (ko) 2005-08-29
KR101215854B1 (ko) 2012-12-31
CN1726290A (zh) 2006-01-25
NO20053344D0 (no) 2005-07-08
HK1087734A1 (en) 2006-10-20
ATE508201T1 (de) 2011-05-15
JP4630067B2 (ja) 2011-02-09
DE10258885A1 (de) 2004-07-15
CA2509333A1 (en) 2004-07-01
WO2004055206A1 (de) 2004-07-01
ZA200504212B (en) 2006-02-22
JP2006509512A (ja) 2006-03-23
US20040143854A1 (en) 2004-07-22
AU2003283409A1 (en) 2004-07-09
CN1726290B (zh) 2012-09-05

Similar Documents

Publication Publication Date Title
NO20053344D0 (no) Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser.
Landsberg et al. Increased cell bond tension governs cell sorting at the Drosophila anteroposterior compartment boundary
ATE269414T1 (de) Verfahren zur drogenuntersuchung
ATE357537T1 (de) Zielgerichtete verfahren des wirkstoff screenings unter verwendung von co-kultivierungs verfahren
ATE516497T1 (de) Screening für funktionshomologien
ATE501998T1 (de) Selektive synthese von organophosphiten
ATE364721T1 (de) Verfahren zum charakterisieren von biologischen bedingungen, die kalibrierte genexpressionsprofile verwenden
DE60039072D1 (de) Verfahren zum screenen von mehrfach transformierteon von fluoreszenzproteinen
AU4929701A (en) Whole-body optical imaging of gene expression and uses thereof
DE60332993D1 (de) Das biomolekültransduktionsmotiv mph-1-btm und dessen verwendung
DE60126115D1 (de) Oberflächentransfektion und expressionsverfahren
DE69033961T2 (de) Zellinien, die einen biologisch aktiven faktor-ix exprimieren
WO2002101039A1 (en) Method of testing drug for treating or preventing diseases such as hyperlipemia
DE69913533D1 (de) Reagentien für cyp2d fluoreszenztest
CY1108126T1 (el) Μεθοδοι ελεγχου διαφοροποιησης και αναπτυξης κυτταρου χρησιμοποιωντας πρωτεϊνη συντηξης και ενα φαρμακο
CY1108849T1 (el) Πολλαπλασιαμος του ιου κορωνα των βοοειδων σε κυτταρα ωοθηκων κινεζικων κρικητων
SE0002189D0 (sv) New method and assay
WO2003094841A3 (en) Mammalian genes involed in rapamycin resistance and tumorgenesis: annexin xiii genes
ATE501278T1 (de) Verfahren zur verwendung von il-21
DE69916829D1 (de) Genetisch veränderte fibroblasten und ihre verwendung
EP1581645A4 (en) METHOD OF USING INTERRUPTED DIVISION CELLS IN SCREENING TESTS
AU2003241174A1 (en) Method of identifying pancreatic ductal carcinoma-specific gene using pancreatic ductal cells, method of testing for pdc using said genes, and method of screening pharmaceutical candidate compounds for treating or preventing pdc
Mao et al. Characterization of Niche Cells and Signals Regulating Stepwise Embryonic Hematopoiesis Using Slide-Seq and Merfish Spatial Transcriptomics
AU2005291445A1 (en) Improved electrophoretic separation method for analyzing gene expression
ATE446316T1 (de) Chimere proteine zum targeting von zellen und der induktion von apoptose, und verfahren zu deren verwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application